Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023
Digestion · 2024
DOI: 10.1159/000541121 ↗Kurz gefasst
Leitlinie in der Zeitschrift Digestion, 2024. Verfasst von Eikichi Ihara und 36 weiteren Autor:innen. Beteiligte Einrichtung: Guidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological…. Hauptthemen laut MEDLINE: Diarrhea, Probiotics, Evidence-Based Medicine. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The Japan Gastroenterological Association (JGA) published the first version of clinical guidelines for chronic diarrhea 2023. These guidelines describe the definition, classification, diagnostic criteria, diagnostic testing methods, epidemiology, pathophysiology, and treatment of chronic diarrhea, and provide flowcharts for the diagnosis and treatment of chronic diarrhea based on the latest evidence. Treatment for chronic diarrhea begins by distinguishing secondary chronic constipation with a clear etiology, such as drug-induced diarrhea, food-induced diarrhea, systemic disease-associated diarrhea, infection-associated diarrhea, organic disease-associated diarrhea, and bile acid diarrhea. The first line of treatment for chronic diarrhea in the narrow sense, defined in these guidelines as functional diarrhea in routine medical care, is lifestyle modification and dietary therapy. The first medicines to be considered for oral treatment are probiotics for regulating the gut microbiome and anti-diarrheals. Other medications, such as 5HT3 receptor antagonists, anticholinergics, Kampo medicine, psychotherapy, antibiotics, bulking agents, adrenergic agonists, and somatostatin analogs, lack sufficient evidence for their use, highlighting a challenge for future research. This Clinical Guidelines for Chronic Diarrhea 2023, which provides the best clinical strategies for treating chronic diarrhea in Japan, will also be useful for medical treatment worldwide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Zitieren
APA
Ihara, E., Manabe, N., Ohkubo, H., Ogasawara, N., Ogino, H., Kakimoto, K., Kanazawa, M., Kawahara, H., Kusano, C., Kuribayashi, S., Sawada, A., Takagi, T., Takano, S., Tomita, T., Noake, T., Hojo, M., Hokari, R., Masaoka, T., Machida, T., …, & Higuchi, K. (2024). Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023. Digestion. https://doi.org/10.1159/000541121
Vancouver
Ihara E, Manabe N, Ohkubo H, Ogasawara N, Ogino H, Kakimoto K, et al. Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023. Digestion. 2024. doi:10.1159/000541121
BibTeX
@article{Ihara2024,
author = {Ihara, Eikichi and Manabe, Noriaki and Ohkubo, Hidenori and Ogasawara, Naotaka and Ogino, Haruei and Kakimoto, Kazuki and Kanazawa, Motoyori and Kawahara, Hidejiro and Kusano, Chika and Kuribayashi, Shiko and Sawada, Akinari and Takagi, Tomohisa and Takano, Shota and Tomita, Toshihiko and Noake, Toshihiro and Hojo, Mariko and Hokari, Ryota and Masaoka, Tatsuhiro and Machida, Tomohiko and Misawa, Noboru and Mishima, Yoshiyuki and Yajima, Hiroshi and Yamamoto, Sayuri and Yamawaki, Hiroshi and Abe, Tatsuya and Araki, Yasumi and Kasugai, Kunio and Kamiya, Takeshi and Torii, Akira and Nakajima, Atsushi and Nakada, Koji and Fukudo, Shin and Fujiwara, Yasuhiro and Miwa, Hiroto and Kataoka, Hiromi and Nagahara, Akihito and Higuchi, Kazuhide},
title = {Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023},
journal = {Digestion},
year = {2024},
doi = {10.1159/000541121}
}
EUVIMED